A majority of included patients exhibited the iCCA subtype, which is incongruent with the relative incidence rates between subtypes of BTC [2,3,4]; it is, however, consistent with the preponderance of FGFR2 fusions and IDH1 mutations within iCCA, which not only have approved targeted therapies, but are proposed as conferring favourable prognosis irrespective of receiving a targeted therapy, thus improving the likelihood of reaching 3L palliative systemic treatment [31]. This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.